Metabolon Release: Biomarkers of Prostate Cancer Progression Identified with Biochemical Profiling Technology

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced that the company’s global biochemical profiling technology has been used to identify biomarkers indicative of prostate cancer progression. The results of the study, conducted with researchers at the University of Michigan, will be published in the February 12 issue of Nature in a paper titled “Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression”.